检索结果-南通市图书馆

Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC-7721 human hepatocellular carcinoma

引用

Cell Research 1998年第3期8卷 241-247页

作者： SONG YI QIANG GEN FENG WANG XIN LAN DAI HONG XIE(Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China) Shanghai Institute of Cell Biology Chinese Academy of Sciences Shanghai China

The improved tumoricidal effect of the radioatibody mixture ("cocktail") has been reported recently for the treatment of colon tumor. In the present study, we demonstrated the enhanced radioimmunotherapeutic efficacy of a monoclonal atibody (MAb) cocktail against human hepatocellular carcinoma. Therapeutic efficacy was determined by measuring the change in tumor size over a period, determining the percentage of growth inhibition of each treatment at various times after radioantibody therapy. boioimmunotherapy of SMMC-7721 human hepatoma xenografts in athymic nude mice with combination of 131I labeled Hepama-1 and 131Llabeled 9403 mouse MAbs was more effective than using either Hepeam-1 or 9403 Mab alone The MAb cocktail could target a greater number of hepstoma cells and increase the magnitude of hepatoma cen uptde of radioamibodies. The in vjtro results explain the enhanced effect of the MAb cocktail in in vjvo model system.

关键词： Mouse monoclonal antibody human hepatocellular carcinoma radioimmunotherapy antibody cocktail

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Monoclonal Antibodies in Cancer Therapy

引用

Clinical oncology and cancer resexreh 2011年第4期8卷 215-219页

作者： Yu-Ting GUO Qin-Yu HOU Nan WANG Key Laboratory of Industrial FermentationMicrobiology Ministry of Education Tianjin300457 China Tianjin Key Laboratory of Industrial Micro-biology College of Biotechnology TianjinUniversity of Science and TechnologyTianjin 300457 China.

Monoclonal antibodies (MAbs) are a relatively new innovation in cancer treatment. At present, some monoclonal antibodies have increased the efficacy of the treatment of certain tumors with acceptable safety profiles. When monoclonal antibodies enter the body and attach to cancer cells, they function in several different ways: first, they can trigger the immune system to attack and kill that cancer cell; second, they can block the growth signals; third, they can prevent the formation of new blood vessels. Some naked MAbs such as rituximab can be directed to attach to the surface of cancer cells and make them easier for the immune system to find and destroy. The ability to produce antibodies with limited immunogenicity has led to the production and testing of a host of agents, several of which have demonstrated clinically important antitumor activity and have received U.S. Food & Drug Administration (FDA) approval as cancer treatments. To reduce the immunogenicity of murine antibodies, murine molecules are engineered to remove the immunogenic content and to increase their immunologic efficiency. Radiolabeled antibodies composed of antibodies conjugated to radionuclides show efficacy in non-Hodgkin’s lymphoma. Antivascular endothelial growth factor (VEGF) antibodies such as bevacizumab intercept the VEGF signal of tumors, thereby stopping them from connecting with their targets and blocking tumor growth. Trifunctional antibodies have revealed a new perspective in cancer therapy extending beyond primary destruction of tumor cells.

关键词： monoclonal antibody tumor immunogenicity radioimmunotherapy vascular endothelial growth factor.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

TUMOR UPTAKE AND THERAPEUTIC EFFECT OF ASTATINATED INTACT McAb 3H11 AND ITS Fab FRAGMENT FOR HUMAN GASTRIC CANCER XENOGRAFT IN NUDE MICE

引用

Nuclear Science and Techniques 1995年第2期6卷 87-90页

作者：张叔渊金建南刘宁王娟罗林王方元周懋伦罗德元董志伟万文徽 Institute of Nucl Sci and Technol Sichuan Union UniversityChengdu 610064 Institute of Cancer Research West China University of Medical SciencesChengdu 610041 Beijing Institute for Cancer Research Beijing 100034

ＴＵＭＯＲＵＰＴＡＫＥＡＮＤＴＨＥＲＡＰＥＵＴＩＣＥＦＦＥＣＴＯＦＡＳＴＡＴＩＮＡＴＥＤＩＮＴＡＣＴＭｃＡｂ３Ｈ１１ＡＮＤＩＴＳＦａｂＦＲＡＧＭＥＮＴＦＯＲＨＵＭＡＮＧＡＳＴＲＩＣＣＡＮＣＥＲＸＥＮＯＧＲＡＦＴＩＮＮ... 详细信息

ＴＵＭＯＲＵＰＴＡＫＥＡＮＤＴＨＥＲＡＰＥＵＴＩＣＥＦＦＥＣＴＯＦＡＳＴＡＴＩＮＡＴＥＤＩＮＴＡＣＴＭｃＡｂ３Ｈ１１ＡＮＤＩＴＳＦａｂＦＲＡＧＭＥＮＴＦＯＲＨＵＭＡＮＧＡＳＴＲＩＣＣＡＮＣＥＲＸＥＮＯＧＲＡＦＴＩＮＮＵＤＥ　ＭＩＣＥＺｈａｎｇＳｈｕｙ...

关键词： ^(211)At Monoclonal antibody Human gastric cancer radioimmunotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

^(131)I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma

引用

World Journal of Gastroenterology 2013年第47期19卷 9104-9110页

作者： Qing He Wu-Sheng Lu Yang Liu Yong-Song Guan An-Ren Kuang Oncology Department West China Hospital of Sichuan University Department of Vascular Surgery West China Hospital of Sichuan University Department of Psychiatry West China Hospital of Sichuan University Department of Nuclear Medicine West China Hospital of Sichuan University

AIM:To investigate the safety and effectiveness of combined131I-metuximab and transcatheter arterial chemoembolization(TACE)for hepatocellular carcinoma(HCC).METHODS:One hundred and eighty-five patients(159men and 26 women)with advanced HCC were enrolled in this study from February 2009 to July *** were 95 patients in the combined metuximab and TACE group,and 90 patients in the TACE only *** patients were followed for 12 *** symptoms,blood cell counts,Karnofsky Performance Score(KPS)evaluation and therapeutic effects according to the Response Evaluation Criteria in Solid Tumors were recorded and ***:The 1-mo effective rates(complete response+partial response+stable disease)of the test group and control group were 71.23%and 38.89%,respectively(P<0.001).The 6-,9-and 12-mo survival rates were 86.42%,74.07%and 60.49%for the test group and 60.0%,42.22%and 34.44%for the control group(P<0.001).The incidence of adverse events(gastrointestinal symptoms,fever and pain)and blood cell toxicity were significantly higher for the test group than for the control group(P<0.001).No severe131Imetuximab-related complications were *** respect to efficacy,patients in the test group had greater improvement in tumor-related pain(P=0.014)and increase in KPS(P<0.001)than those in the control ***:Combination of131I-metuximab and TACE prolonged the survival time in patients with HCC compared with TACE *** combination treatment was safe and effective.

关键词： Hepatocellular carcinoma 131 I-metuximab Transcatheter arterial chemoembolization radioimmunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：